PTC Therapeutics | PTCT - Selling And Administration Expenses

Stock Price
64.49
Daily Change
1.13 1.78%
Monthly
-6.77%
Yearly
18.33%
Q1 Forecast
62.54

PTC Therapeutics reported $87.2M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025